Use access key #2 to skip to page content.
$0.34 -0.02 (-4.82%)
10/6/2008 3:59 PM

Generex Biotechnology Corp (GNBT)

CAPS Rating:
***

The Company is engaged primarily in the research, development and commercialization of drug delivery systems and technologies.

View All Commentary (GNBT)

Recs

2

Avatar Voyt608 (< 20) Submitted: 1/07/08 9:51 PM : Outperform Start Price: $1.59 GNBT Score: -52.32

GNBT's Oral insulin delivery system is a significant advancement in the treatment of Diabetes Mellitus and will be soon approved for use in the USA. It will be a cash cow, funding the companies cancer treatment programs for the foreseeable future.


I expect GNBT to be a blockbuster stock.

Report this Post Replies: 0 | Reply

Featured Broker Partners